Question normal

“It’s the first targeted personalized medicine that had ever been used.”

"Everyone hopes and wishes for that last-minute cancer breakthrough that will save doomed patients. It almost never actually happens. With Gleevec, it did.

The once-a-day pill turned chronic myelogenous leukemia, or CML, from a certain death sentence into a manageable disease. Now data shows it's helped 83 percent of patients live 10 years or longer, even with side-effects that include a characteristic rash, nausea and fatigue."

Call in to hear the incredible story of imatinib from Dr. Drucker himself at our Interactive Session on 3/22!

Please join us on March 22, 2017 at 5:00pm EDT. Join the webinar online or dial in to participate:

Webinar URL:

Dial In Information:
United States: +1 (872) 240-3412
Access Code: 182-533-19